Jerry Colca
Chief Scientific Officer Cirius Therapeutics
Seminars
Thursday 16th April 2026
Redefining the Patient Journey by Leveraging Oral MPC Modulation to Enhance GLP-1 Tolerability and Preserve Lean Mass
3:30 pm
- Utilizing a novel oral Mitochondrial Pyruvate Carrier (MPC) modulator (azemiglitazone) with GLP-1 Receptor Agonists, as evidenced by preclinical and early clinical data showing enhanced metabolic control (improved insulin sensitivity, reduced liver fat) and synergistic efficacy in reducing underlying metabolic dysfunction in Type 2 Diabetes and MASH
- Focusing on the MPC modulator’s potential to preserve or increase lean mass while optimizing fat loss, establishing a path for long-term patient health and adherence that is critical to redefining the patient journey beyond mere weight reduction
- Defining the strategy for next-generation metabolic therapeutics that layer novel oral, non-incretin mechanisms onto incretin backbones to significantly enhance patient comfort and compliance by allowing for lower, better-tolerated doses of the GLP-1 component and establishing a more robust, long-term safety profile
